Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection

Dustin B. Hammers; Ani Eloyan; Alexander Taurone; Maryanne Thangarajah; Laurel Beckett; Sujuan Gao; Kala Kirby; Paul Aisen; Jeffrey L. Dage; Tatiana Foroud; Percy Griffin; Lea T. Grinberg; Clifford R. Jack; Joel Kramer; Robert Koeppe; Walter A. Kukull; Nidhi S. Mundada; Renaud La Joie; David N. Soleimani-Meigooni; Leonardo Iaccarino; Melissa E. Murray; Kelly Nudelman; Angelina J. Polsinelli; Malia Rumbaugh; Arthur Toga; Alexandra Touroutoglou; Prashanthi Vemuri; Alireza Atri; Gregory S. Day; Ranjan Duara; Neill R. Graff-Radford; Lawrence S. Honig; David T. Jones; Joseph Masdeu; Mario F. Mendez; Kyle Womack; Erik Musiek; Chiadi U. Onyike; Meghan Riddle; Emily Rogalski; Steven Salloway; Sharon J. Sha; Raymond Scott Turner; Thomas S. Wingo; David A. Wolk; Maria C. Carrillo; Bradford C. Dickerson; Gil D. Rabinovici; Liana G. Apostolova

doi:10.1002/alz.13160

Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection

Dustin B. Hammers, Ani Eloyan, Alexander Taurone, Maryanne Thangarajah, Laurel Beckett, Sujuan Gao, Kala Kirby, Paul Aisen, Jeffrey L. Dage, Tatiana Foroud, Percy Griffin, Lea T. Grinberg, Clifford R. Jack, Joel Kramer, Robert Koeppe, Walter A. Kukull, Nidhi S. Mundada, Renaud La Joie, David N. Soleimani-Meigooni, Leonardo IaccarinoMelissa E. Murray, Kelly Nudelman, Angelina J. Polsinelli, Malia Rumbaugh, Arthur Toga, Alexandra Touroutoglou, Prashanthi Vemuri, Alireza Atri, Gregory S. Day, Ranjan Duara, Neill R. Graff-Radford, Lawrence S. Honig, David T. Jones, Joseph Masdeu, Mario F. Mendez, Kyle Womack, Erik Musiek, Chiadi U. Onyike, Meghan Riddle, Emily Rogalski, Steven Salloway, Sharon J. Sha, Raymond Scott Turner, Thomas S. Wingo, David A. Wolk, Maria C. Carrillo, Bradford C. Dickerson, Gil D. Rabinovici, Liana G. Apostolova

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

OBJECTIVE: The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) seeks to provide comprehensive understanding of early-onset Alzheimer's disease (EOAD; onset <65 years), with the current study profiling baseline clinical, cognitive, biomarker, and genetic characteristics of the cohort nearing the data-collection mid-point.

METHODS: Data from 371 LEADS participants were compared based on diagnostic group classification (cognitively normal [n = 89], amyloid-positive EOAD [n = 212], and amyloid-negative early-onset non-Alzheimer's disease [EOnonAD; n = 70]).

RESULTS: Cognitive performance was worse for EOAD than other groups, and EOAD participants were apolipoprotein E (APOE) ε4 homozygotes at higher rates. An amnestic presentation was common among impaired participants (81%), with several clinical phenotypes present. LEADS participants generally consented at high rates to optional trial procedures.

CONCLUSIONS: We present the most comprehensive baseline characterization of sporadic EOAD in the United States to date. EOAD presents with widespread cognitive impairment within and across clinical phenotypes, with differences in APOE ε4 allele carrier status appearing to be relevant.

HIGHLIGHTS: Findings represent the most comprehensive baseline characterization of sporadic early-onset Alzheimer's disease (EOAD) to date. Cognitive impairment was widespread for EOAD participants and more severe than other groups. EOAD participants were homozygous apolipoprotein E (APOE) ε4 carriers at higher rates than the EOnonAD group. Amnestic presentation predominated in EOAD and EOnonAD participants, but other clinical phenotypes were present.

Original language	English (US)
Pages (from-to)	S8-S18
Journal	Alzheimer's and Dementia
Volume	19 Suppl 9
Issue number	S9
Early online date	May 31 2023
DOIs	https://doi.org/10.1002/alz.13160
State	Published - Nov 2023

Keywords

Alzheimer's disease
amnestic
atypical variant
early-onset
memory
Apolipoproteins E/genetics
Alzheimer Disease/genetics
Humans
Data Collection
Longitudinal Studies
Apolipoprotein E4/genetics

ASJC Scopus subject areas

Clinical Neurology
Geriatrics and Gerontology
Psychiatry and Mental health
Cellular and Molecular Neuroscience
Health Policy
Developmental Neuroscience
Epidemiology

Access to Document

10.1002/alz.13160

Cite this

Hammers, D. B., Eloyan, A., Taurone, A., Thangarajah, M., Beckett, L., Gao, S., Kirby, K., Aisen, P., Dage, J. L., Foroud, T., Griffin, P., Grinberg, L. T., Jack, C. R., Kramer, J., Koeppe, R., Kukull, W. A., Mundada, N. S., La Joie, R., Soleimani-Meigooni, D. N., ... Apostolova, L. G. (2023). Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection. Alzheimer's and Dementia, 19 Suppl 9(S9), S8-S18. https://doi.org/10.1002/alz.13160

Hammers, DB, Eloyan, A, Taurone, A, Thangarajah, M, Beckett, L, Gao, S, Kirby, K, Aisen, P, Dage, JL, Foroud, T, Griffin, P, Grinberg, LT, Jack, CR, Kramer, J, Koeppe, R, Kukull, WA, Mundada, NS, La Joie, R, Soleimani-Meigooni, DN, Iaccarino, L, Murray, ME, Nudelman, K, Polsinelli, AJ, Rumbaugh, M, Toga, A, Touroutoglou, A, Vemuri, P, Atri, A, Day, GS, Duara, R, Graff-Radford, NR, Honig, LS, Jones, DT, Masdeu, J, Mendez, MF, Womack, K, Musiek, E, Onyike, CU, Riddle, M, Rogalski, E, Salloway, S, Sha, SJ, Turner, RS, Wingo, TS, Wolk, DA, Carrillo, MC, Dickerson, BC, Rabinovici, GD & Apostolova, LG 2023, 'Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection', Alzheimer's and Dementia, vol. 19 Suppl 9, no. S9, pp. S8-S18. https://doi.org/10.1002/alz.13160

@article{c77a97e63048459fbb4c874a92da845e,

title = "Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection",

abstract = "OBJECTIVE: The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) seeks to provide comprehensive understanding of early-onset Alzheimer's disease (EOAD; onset <65 years), with the current study profiling baseline clinical, cognitive, biomarker, and genetic characteristics of the cohort nearing the data-collection mid-point.METHODS: Data from 371 LEADS participants were compared based on diagnostic group classification (cognitively normal [n = 89], amyloid-positive EOAD [n = 212], and amyloid-negative early-onset non-Alzheimer's disease [EOnonAD; n = 70]).RESULTS: Cognitive performance was worse for EOAD than other groups, and EOAD participants were apolipoprotein E (APOE) ε4 homozygotes at higher rates. An amnestic presentation was common among impaired participants (81%), with several clinical phenotypes present. LEADS participants generally consented at high rates to optional trial procedures.CONCLUSIONS: We present the most comprehensive baseline characterization of sporadic EOAD in the United States to date. EOAD presents with widespread cognitive impairment within and across clinical phenotypes, with differences in APOE ε4 allele carrier status appearing to be relevant.HIGHLIGHTS: Findings represent the most comprehensive baseline characterization of sporadic early-onset Alzheimer's disease (EOAD) to date. Cognitive impairment was widespread for EOAD participants and more severe than other groups. EOAD participants were homozygous apolipoprotein E (APOE) ε4 carriers at higher rates than the EOnonAD group. Amnestic presentation predominated in EOAD and EOnonAD participants, but other clinical phenotypes were present.",

keywords = "Alzheimer's disease, amnestic, atypical variant, early-onset, memory, Apolipoproteins E/genetics, Alzheimer Disease/genetics, Humans, Data Collection, Longitudinal Studies, Apolipoprotein E4/genetics",

author = "Hammers, {Dustin B.} and Ani Eloyan and Alexander Taurone and Maryanne Thangarajah and Laurel Beckett and Sujuan Gao and Kala Kirby and Paul Aisen and Dage, {Jeffrey L.} and Tatiana Foroud and Percy Griffin and Grinberg, {Lea T.} and Jack, {Clifford R.} and Joel Kramer and Robert Koeppe and Kukull, {Walter A.} and Mundada, {Nidhi S.} and {La Joie}, Renaud and Soleimani-Meigooni, {David N.} and Leonardo Iaccarino and Murray, {Melissa E.} and Kelly Nudelman and Polsinelli, {Angelina J.} and Malia Rumbaugh and Arthur Toga and Alexandra Touroutoglou and Prashanthi Vemuri and Alireza Atri and Day, {Gregory S.} and Ranjan Duara and Graff-Radford, {Neill R.} and Honig, {Lawrence S.} and Jones, {David T.} and Joseph Masdeu and Mendez, {Mario F.} and Kyle Womack and Erik Musiek and Onyike, {Chiadi U.} and Meghan Riddle and Emily Rogalski and Steven Salloway and Sha, {Sharon J.} and Turner, {Raymond Scott} and Wingo, {Thomas S.} and Wolk, {David A.} and Carrillo, {Maria C.} and Dickerson, {Bradford C.} and Rabinovici, {Gil D.} and Apostolova, {Liana G.}",

note = "Publisher Copyright: {\textcopyright} 2023 the Alzheimer's Association.",

year = "2023",

month = nov,

doi = "10.1002/alz.13160",

language = "English (US)",

volume = "19 Suppl 9",

pages = "S8--S18",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "S9",

}

TY - JOUR

T1 - Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection

AU - Hammers, Dustin B.

AU - Eloyan, Ani

AU - Taurone, Alexander

AU - Thangarajah, Maryanne

AU - Beckett, Laurel

AU - Gao, Sujuan

AU - Kirby, Kala

AU - Aisen, Paul

AU - Dage, Jeffrey L.

AU - Foroud, Tatiana

AU - Griffin, Percy

AU - Grinberg, Lea T.

AU - Jack, Clifford R.

AU - Kramer, Joel

AU - Koeppe, Robert

AU - Kukull, Walter A.

AU - Mundada, Nidhi S.

AU - La Joie, Renaud

AU - Soleimani-Meigooni, David N.

AU - Iaccarino, Leonardo

AU - Murray, Melissa E.

AU - Nudelman, Kelly

AU - Polsinelli, Angelina J.

AU - Rumbaugh, Malia

AU - Toga, Arthur

AU - Touroutoglou, Alexandra

AU - Vemuri, Prashanthi

AU - Atri, Alireza

AU - Day, Gregory S.

AU - Duara, Ranjan

AU - Graff-Radford, Neill R.

AU - Honig, Lawrence S.

AU - Jones, David T.

AU - Masdeu, Joseph

AU - Mendez, Mario F.

AU - Womack, Kyle

AU - Musiek, Erik

AU - Onyike, Chiadi U.

AU - Riddle, Meghan

AU - Rogalski, Emily

AU - Salloway, Steven

AU - Sha, Sharon J.

AU - Turner, Raymond Scott

AU - Wingo, Thomas S.

AU - Wolk, David A.

AU - Carrillo, Maria C.

AU - Dickerson, Bradford C.

AU - Rabinovici, Gil D.

AU - Apostolova, Liana G.

PY - 2023/11

Y1 - 2023/11

N2 - OBJECTIVE: The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) seeks to provide comprehensive understanding of early-onset Alzheimer's disease (EOAD; onset <65 years), with the current study profiling baseline clinical, cognitive, biomarker, and genetic characteristics of the cohort nearing the data-collection mid-point.METHODS: Data from 371 LEADS participants were compared based on diagnostic group classification (cognitively normal [n = 89], amyloid-positive EOAD [n = 212], and amyloid-negative early-onset non-Alzheimer's disease [EOnonAD; n = 70]).RESULTS: Cognitive performance was worse for EOAD than other groups, and EOAD participants were apolipoprotein E (APOE) ε4 homozygotes at higher rates. An amnestic presentation was common among impaired participants (81%), with several clinical phenotypes present. LEADS participants generally consented at high rates to optional trial procedures.CONCLUSIONS: We present the most comprehensive baseline characterization of sporadic EOAD in the United States to date. EOAD presents with widespread cognitive impairment within and across clinical phenotypes, with differences in APOE ε4 allele carrier status appearing to be relevant.HIGHLIGHTS: Findings represent the most comprehensive baseline characterization of sporadic early-onset Alzheimer's disease (EOAD) to date. Cognitive impairment was widespread for EOAD participants and more severe than other groups. EOAD participants were homozygous apolipoprotein E (APOE) ε4 carriers at higher rates than the EOnonAD group. Amnestic presentation predominated in EOAD and EOnonAD participants, but other clinical phenotypes were present.

AB - OBJECTIVE: The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) seeks to provide comprehensive understanding of early-onset Alzheimer's disease (EOAD; onset <65 years), with the current study profiling baseline clinical, cognitive, biomarker, and genetic characteristics of the cohort nearing the data-collection mid-point.METHODS: Data from 371 LEADS participants were compared based on diagnostic group classification (cognitively normal [n = 89], amyloid-positive EOAD [n = 212], and amyloid-negative early-onset non-Alzheimer's disease [EOnonAD; n = 70]).RESULTS: Cognitive performance was worse for EOAD than other groups, and EOAD participants were apolipoprotein E (APOE) ε4 homozygotes at higher rates. An amnestic presentation was common among impaired participants (81%), with several clinical phenotypes present. LEADS participants generally consented at high rates to optional trial procedures.CONCLUSIONS: We present the most comprehensive baseline characterization of sporadic EOAD in the United States to date. EOAD presents with widespread cognitive impairment within and across clinical phenotypes, with differences in APOE ε4 allele carrier status appearing to be relevant.HIGHLIGHTS: Findings represent the most comprehensive baseline characterization of sporadic early-onset Alzheimer's disease (EOAD) to date. Cognitive impairment was widespread for EOAD participants and more severe than other groups. EOAD participants were homozygous apolipoprotein E (APOE) ε4 carriers at higher rates than the EOnonAD group. Amnestic presentation predominated in EOAD and EOnonAD participants, but other clinical phenotypes were present.

KW - Alzheimer's disease

KW - amnestic

KW - atypical variant

KW - early-onset

KW - memory

KW - Apolipoproteins E/genetics

KW - Alzheimer Disease/genetics

KW - Humans

KW - Data Collection

KW - Longitudinal Studies

KW - Apolipoprotein E4/genetics

UR - http://www.scopus.com/inward/record.url?scp=85161440852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85161440852&partnerID=8YFLogxK

U2 - 10.1002/alz.13160

DO - 10.1002/alz.13160

M3 - Article

C2 - 37256497

AN - SCOPUS:85161440852

SN - 1552-5260

VL - 19 Suppl 9

SP - S8-S18

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - S9

ER -

Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this